Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal clarithromycin plus Glucantime versus Glucantime plus placebo for cutaneous leishmaniasis
IRCT20171230038142N17Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of clarithromycin and meglumine antimoniate in cutaneous leishmaniasis (CL) (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Lesion size, Frequency of lesions and 1 more. Started Dec 2019; status: completed.
02
Drugs
clarithromycinmeglumine antimoniate
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on IRCT20171230038142N17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20171230038142N17.